Objectives: Our aim of this study is to compare the effect of Dexmedetomidine versus placebo for patients with cerebral protection during intracranial procedures.
Methods: Rev.Man 5.1 and Stata 11.0 software is used for this study to make analysis, and use a fixed-effects model (the Mantel-Haenszel method) or a random-effects model (the DerSimonian and Laird method) to merge or aggregate the weighted mean difference (WMD) or risk ratio (RR) and its 95% confidence intervals (CI) of included studies.
Results: Nine studies involving 404 patients with cerebral protection during intracranial procedures (experimental group: 202; control group: 202) were performed in this study. Significant differences of MAP > 100 mmHg(RR = 0.45, 95%CI = 0.29 to 0.69, P < 0.05), MAP< 60 mmHg (RR = 0.66, 95%CI = 0.43 to 1.00, P = 0.05), MAP when extubation (WMD = -12.57, 95%CI = -16.31 to -8.83, P < 0.05) and heart rate when extubation (WMD = -22.79, 95%CI = -30.57 to -15.01, P < 0.05) were observed between the two groups. There are no significant differences were found in HR > 100 bpm (RR = 0.52, 95%CI = 0.22 to 1.19, P > 0.05) and HR< 50 bpm (RR = 0.86, 95%CI = 0.31 to 2.38, P > 0.05) between the two groups.
Conclusions: Our results suggested that the efficacy of Dexmedetomidine for patients with cerebral protection during intracranial procedures is better than placebo treatment.
Keywords: Dexmedetomidine; cerebral protection; meta-analysis.